Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 10, 2022 08:00 ET | Source: Surrozen, Inc.

Surrozen Announces Key 2022 Milestones for Lead Programs and Acceleration of Research Pipeline

-Initiation of Phase 1 clinical trials of SZN-1326 and SZN-043 expected in third quarter 2022 -Acceleration of preclinical programs includes nomination of lead candidate SZN-413 for retinopathies and...
January 05, 2022 08:00 ET | Source: Surrozen, Inc.

Surrozen to Present Virtually at the 40th Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the...
November 15, 2021 16:00 ET | Source: Surrozen, Inc.

Surrozen Reports Third Quarter 2021 Financial Results

Product Candidates SZN-1326 and SZN-043 Advance Toward Initiation of Clinical Studies in 2022 Expanding and Advancing Discovery Stage Pipeline in Multiple Disease Settings SOUTH SAN FRANCISCO,...
November 15, 2021 08:00 ET | Source: Surrozen, Inc.

Surrozen Presents Data Supporting Potential of SZN-043 at The Liver Meeting 2021, the Annual Meeting of the American Association for the Study of Liver Diseases

SOUTH SAN FRANCISCO, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Surrozen, Inc. (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair...
November 15, 2021 08:00 ET | Source: Surrozen, Inc.

Surrozen to Present at The Piper Sandler 33rd Annual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Surrozen, Inc., (NASDAQ: SRZN), a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt...
November 05, 2021 08:00 ET | Source: Surrozen, Inc.

Surrozen to Present at The Stifel 2021 Virtual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov. 05, 2021 (GLOBE NEWSWIRE) -- Surrozen, Inc., (Nasdaq: SRZN), a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt...
October 05, 2021 16:30 ET | Source: Surrozen, Inc.

Surrozen Presented Data Supporting Potential of SZN-1326 at the 2021 United European Gastroenterology Week

SOUTH SAN FRANCISCO, Calif., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Surrozen, Inc. (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair...
September 23, 2021 08:30 ET | Source: Surrozen, Inc.

Surrozen Announces Appointment of Liz Nguyen as Vice President and Head of Human Resources

SOUTH SAN FRANCISCO, Calif., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Surrozen Inc. (Nasdaq: SRZN), a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt...
August 11, 2021 17:30 ET | Source: Surrozen, Inc.

Surrozen Debuts as Publicly Traded Leader in Wnt Biology and Tissue Regeneration

SOUTH SAN FRANCISCO, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen”), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and...
August 05, 2021 08:00 ET | Source: Surrozen, Inc.

Surrozen to Present at Canaccord Genuity’s 41st Annual Growth Conference

SOUTH SAN FRANCISCO, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Surrozen Inc. (Nasdaq: SRZN), a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right